Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Nurix appoints Robert Tjian as chairman of Scientific Advisory Board » 08:39
10/26/20
10/26
08:39
10/26/20
08:39
NRIX

Nurix Therapeutics

$28.21 /

+0.76 (+2.77%)

Nurix Therapeutics…

Nurix Therapeutics announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company's Board of Directors effective November 1, 2020. Dr. Tjian has served as a member of the Board of Directors since November 2016. Dr. Tjian will continue to provide guidance and advice to Nurix in his new role as Chairman of Nurix's Scientific Advisory Board.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$28.21 /

+0.76 (+2.77%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
NRIX Nurix Therapeutics
$28.21 /

+0.76 (+2.77%)

  • 24
    Jul
NRIX Nurix Therapeutics
$28.21 /

+0.76 (+2.77%)

Over a week ago
Conference/Events
Nurix Therapeutics management to meet virtually with Needham » 05:55
10/20/20
10/20
05:55
10/20/20
05:55
NRIX

Nurix Therapeutics

$26.49 /

+1.39 (+5.54%)

Virtual Meeting to be…

Virtual Meeting to be held October 19-20 hosted by Needham.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$26.49 /

+1.39 (+5.54%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
NRIX Nurix Therapeutics
$26.49 /

+1.39 (+5.54%)

  • 24
    Jul
NRIX Nurix Therapeutics
$26.49 /

+1.39 (+5.54%)

Conference/Events
Nurix Therapeutics management to meet virtually with Needham » 04:55
10/19/20
10/19
04:55
10/19/20
04:55
NRIX

Nurix Therapeutics

$25.47 /

+1.155 (+4.75%)

Virtual Meeting to be…

Virtual Meeting to be held October 19-20 hosted by Needham.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$25.47 /

+1.155 (+4.75%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
NRIX Nurix Therapeutics
$25.47 /

+1.155 (+4.75%)

  • 24
    Jul
NRIX Nurix Therapeutics
$25.47 /

+1.155 (+4.75%)

Conference/Events
Nurix Therapeutics management to meet virtually with Needham » 10:41
10/16/20
10/16
10:41
10/16/20
10:41
NRIX

Nurix Therapeutics

$24.25 /

-0.065 (-0.27%)

Virtual Meeting to be…

Virtual Meeting to be held October 19-20 hosted by Needham.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$24.25 /

-0.065 (-0.27%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
NRIX Nurix Therapeutics
$24.25 /

-0.065 (-0.27%)

  • 24
    Jul
NRIX Nurix Therapeutics
$24.25 /

-0.065 (-0.27%)

Earnings
Nurix Therapeutics reports Q3 EPS (59c), consensus (41c) » 16:21
10/14/20
10/14
16:21
10/14/20
16:21
NRIX

Nurix Therapeutics

$24.90 /

-1.2 (-4.60%)

Reports Q3 revenue $4.1M,…

Reports Q3 revenue $4.1M, consensus $6.3M.As of August 31, 2020, the Company had cash, cash equivalents and investments of $395.1 million compared to $38.2 million as of November 30, 2019.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$24.90 /

-1.2 (-4.60%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
  • 24
    Jul
NRIX Nurix Therapeutics
$24.90 /

-1.2 (-4.60%)

Conference/Events
Nurix Therapeutics participates in a conference call with JPMorgan » 10:11
10/06/20
10/06
10:11
10/06/20
10:11
NRIX

Nurix Therapeutics

$26.97 /

+0.89 (+3.41%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Joseph holds a conference call with CEO Sands on October 6 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$26.97 /

+0.89 (+3.41%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
  • 24
    Jul
NRIX Nurix Therapeutics
$26.97 /

+0.89 (+3.41%)

Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 09:49
08/18/20
08/18
09:49
08/18/20
09:49
MCRB

Seres Therapeutics

$27.18 /

+0.94 (+3.58%)

, VOYA

Voya Financial

$51.68 /

+0.45 (+0.88%)

, INZY

Inozyme

$31.00 /

+2.25 (+7.83%)

, ANNX

Annexon

$26.52 /

+ (+0.00%)

, NRIX

Nurix Therapeutics

$27.00 /

+ (+0.00%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Seres Therapeutics (MCRB) initiated with an Overweight at Piper Sandler. 2. Voya Financial (VOYA) initiated with an Overweight at Wells Fargo. 3. Inozyme (INZY) initiated with an Overweight at Piper Sandler, an Outperform at Cowen, a Buy at BofA and an Outperform at Wedbush. 4. Annexon (ANNX) initiated with a Buy at BofA, an Outperform at Cowen and an Overweight at JPMorgan. 5. Nurix Therapeutics (NRIX) initiated with an Overweight at Piper Sandler, a Buy at Needham, a Buy at Stifel and an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VOYA Voya Financial
$51.68 /

+0.45 (+0.88%)

MCRB Seres Therapeutics
$27.18 /

+0.94 (+3.58%)

ANNX Annexon
$26.52 /

+ (+0.00%)

MCRB Seres Therapeutics
$27.18 /

+0.94 (+3.58%)

08/18/20 Piper Sandler
Seres Therapeutics initiated with an Overweight at Piper Sandler
08/11/20 H.C. Wainwright
Seres Therapeutics price target raised to $41 from $8 at H.C. Wainwright
08/11/20 Jefferies
Seres Therapeutics upgraded to Buy from Hold at Jefferies
08/11/20 Jefferies
Seres Therapeutics upgraded to Buy from Hold at Jefferies
VOYA Voya Financial
$51.68 /

+0.45 (+0.88%)

08/18/20 Wells Fargo
Wells Fargo starts Voya Financial with Overweight, $62 price target
08/18/20 Wells Fargo
Voya Financial initiated with an Overweight at Wells Fargo
08/13/20 Truist
Voya Financial price target raised to $53 from $45 at Truist
08/13/20 Barclays
Voya Financial initiated with an Overweight at Barclays
INZY Inozyme
$31.00 /

+2.25 (+7.83%)

08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
08/18/20 BofA
Inozyme initiated with a Buy at BofA
08/18/20 Cowen
Inozyme initiated with an Outperform at Cowen
ANNX Annexon
$26.52 /

+ (+0.00%)

08/18/20 JPMorgan
Annexon initiated with an Overweight at JPMorgan
08/18/20 BofA
Annexon initiated with a Buy at BofA
08/18/20 Cowen
Annexon initiated with an Outperform at Cowen
08/18/20 BofA
Annexon initiated with a Buy at BofA
NRIX Nurix Therapeutics
$27.00 /

+ (+0.00%)

08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
VOYA Voya Financial
$51.68 /

+0.45 (+0.88%)

MCRB Seres Therapeutics
$27.18 /

+0.94 (+3.58%)

  • 13
    Aug
  • 24
    Jul
  • 24
    Jul
  • 24
    Jul
MCRB Seres Therapeutics
$27.18 /

+0.94 (+3.58%)

INZY Inozyme
$31.00 /

+2.25 (+7.83%)

MCRB Seres Therapeutics
$27.18 /

+0.94 (+3.58%)

Initiation
Nurix Therapeutics initiated with an Overweight at JPMorgan » 08:46
08/18/20
08/18
08:46
08/18/20
08:46
NRIX

Nurix Therapeutics

$27.00 /

+3.45 (+14.65%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph initiated coverage of Nurix Therapeutics with an Overweight rating and $35 price target. The analyst views Nurix as a "differentiated name" within the emerging oral target protein degrader space, with "compelling and innovative" shots on goal in the arenas of precision and immune oncology. He sees higher than Street-implied success expectations for the company's lead BTK degrader candidate NX-2127.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$27.00 /

+3.45 (+14.65%)

08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Piper Sandler
Nurix Therapeutics initiated with an Overweight at Piper Sandler
  • 24
    Jul
NRIX Nurix Therapeutics
$27.00 /

+3.45 (+14.65%)

Initiation
Nurix Therapeutics initiated with a Buy at Needham » 07:49
08/18/20
08/18
07:49
08/18/20
07:49
NRIX

Nurix Therapeutics

$27.00 /

+3.45 (+14.65%)

Needham analyst Chad…

Needham analyst Chad Messer initiated coverage of Nurix Therapeutics with a Buy rating and $35 price target. The company's ubiquitin ligase system for targeted protein degradation "has the potential to revolutionize drug development", the analyst tells investors in a research note, allowing for the "unique" development of both E3 ligase engagers and inhibitors. Nurix' offers a "differentiated approach and exciting leads", which position the company at the forefront of this "rapidly expanding new field", Messer adds.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$27.00 /

+3.45 (+14.65%)

08/18/20 Stifel
Nurix Therapeutics initiated with a Buy at Stifel
08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Piper Sandler
Nurix Therapeutics initiated with an Overweight at Piper Sandler
  • 24
    Jul
NRIX Nurix Therapeutics
$27.00 /

+3.45 (+14.65%)

Initiation
Nurix Therapeutics initiated with a Buy at Stifel » 06:49
08/18/20
08/18
06:49
08/18/20
06:49
NRIX

Nurix Therapeutics

$27.00 /

+3.45 (+14.65%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey initiated coverage of Nurix Therapeutics with a Buy rating and $34 price target. Willey believes the company's current preclinical pipeline of BTK-targeted degraders and CBL-B inhibitors represent first-in-class/high-value opportunities, while current collaborative agreements and strategic initiatives provide an unparalleled breadth of longer-term optionality which he says isn't accurately reflected in the current valuation.

ShowHide Related Items >><<
NRIX Nurix Therapeutics
$27.00 /

+3.45 (+14.65%)

08/18/20 Needham
Nurix Therapeutics initiated with a Buy at Needham
08/18/20 Piper Sandler
Nurix Therapeutics initiated with an Overweight at Piper Sandler
  • 24
    Jul
NRIX Nurix Therapeutics
$27.00 /

+3.45 (+14.65%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.